A comprehensive review of imaging findings in COVID-19 - status in early 2021
Ali Afshar-Oromieh,Helmut Prosch,Cornelia Schaefer-Prokop,Karl Peter Bohn,Ian Alberts,Clemens Mingels,Majda Thurnher,Paul Cumming,Kuangyu Shi,Alan Peters,Silvana Geleff,Xiaoli Lan,Feng Wang,Adrian Huber,Christoph Gräni,Johannes T. Heverhagen,Axel Rominger,Matthias Fontanellaz,Heiko Schöder,Andreas Christe,Stavroula Mougiakakou,Lukas Ebner
DOI: https://doi.org/10.1007/s00259-021-05375-3
2021-05-01
Abstract:Abstract Medical imaging methods are assuming a greater role in the workup of patients with COVID-19, mainly in relation to the primary manifestation of pulmonary disease and the tissue distribution of the angiotensin-converting-enzyme 2 (ACE 2) receptor. However, the field is so new that no consensus view has emerged guiding clinical decisions to employ imaging procedures such as radiography, computer tomography (CT), positron emission tomography (PET), and magnetic resonance imaging, and in what measure the risk of exposure of staff to possible infection could be justified by the knowledge gained. The insensitivity of current RT-PCR methods for positive diagnosis is part of the rationale for resorting to imaging procedures. While CT is more sensitive than genetic testing in hospitalized patients, positive findings of ground glass opacities depend on the disease stage. There is sparse reporting on PET/CT with [ 18 F]-FDG in COVID-19, but available results are congruent with the earlier literature on viral pneumonias. There is a high incidence of cerebral findings in COVID-19, and likewise evidence of gastrointestinal involvement. Artificial intelligence, notably machine learning is emerging as an effective method for diagnostic image analysis, with performance in the discriminative diagnosis of diagnosis of COVID-19 pneumonia comparable to that of human practitioners.
radiology, nuclear medicine & medical imaging